Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

[Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome]. Giornale italiano di cardiologia (2006) Potena, L., Ferrara, R., Mocarski, E. S., Lewis, D. B., Cooke, J. P., Grigioni, F., Coccolo, F., Magnani, G., Fallani, F., Magelli, C., Valantine, H. A., Branzi, A. 2007; 8 (2): 73-82

Abstract

Cardiac allograft vasculopathy is still the main cause of long-term graft loss after heart transplantation. Indeed, recent advances in immunosuppression management led to a significant improvement in short-term survival, while long-term death rate did not change significantly in the last 20 years. In this paper, we will review the latest advances in the understanding of this peculiar form of atherosclerosis, focusing on the mechanisms that can be potentially targeted by specific therapeutic interventions.

View details for PubMedID 17402351